Risk of Recurrent Venous Thromboembolism and Bleeding in Cancer Patients Treated with Direct Oral Anticoagulants Versus Low Molecular Weight Heparin
Benefits in NNT
1 in 41 were helped (recurrent VTE prevented)
2.44% were helped (lower risk of recurrent VTE)
Harms in NNT
No one was harmed (no significant difference in risk of major bleeding compared to LMWH)
No one was harmed
SourceDong Y, Wang Y, Ma RL, Liu M, Gao JZ, Su WY, et al. Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer: a systematic review and meta-analysis. J Thromb Thrombolysis. 2019 May 6. doi: 10.1007/s11239-019- 01871-4.
Study Population: 11 studies of 4509 patients (1868 patients receiving DOACs and 2641 patients receiving LMWH)
Efficacy EndpointsRecurrent VTE
Harm EndpointsMajor bleeding
NarrativeVenous thromboembolism (VTE) occurs in up to 30% of patients with cancer.1, 2 Prior guidelines have recommended low molecular weight heparin (LMWH) for 3-6 months as first-line therapy in cancer patients with newly-diagnosed VTE.3, 4, 5 Unfortunately, LMWH is associated with poor compliance due to the need for subcutaneous injection.6, 7 Direct oral anticoagulants (DOACs) have been increasingly used for the treatment of VTE, are administered orally with no requirement for regular laboratory monitoring, and may have fewer drug-drug interactions as compared with warfarin, despite DOACs possessing a greater cost compared to other therapies. Several more recent guidelines, including the National Comprehensive Cancer Network (NCCN) and International Society on Thrombosis and Haemostasis (ISTH), recommend DOACs, based on limited data.8, 9 However, other guidelines including the American Society of Clinical Oncology still preferentially recommend LMWH,10 and DOAC efficacy and safety remain controversial in patients with cancer and acute VTE when compared to LMWH.
This systematic review and meta-analysis included studies comparing DOACs with LMWH for the treatment of VTE in patients with cancer.11 The primary outcomes were VTE recurrence and major bleeding in patients with cancer receiving DOACs or LMWH. Major bleeding was defined as clinically overt bleeding associated with a decrease in hemoglobin of 2 g/dL or more, requiring transfusion of two or more units of blood, occurring in a critical site (e.g. intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial or intramuscular with compartment syndrome), or fatal bleeding as per ISTH criteria. Authors conducted subgroup analyses based on study design, specific medication, and duration of follow-up.
The authors identified 11 relevant studies (n=4509), with 2 randomized controlled trials (RCTs) (1 trial each evaluating edoxaban and rivaroxaban) and 9 observational cohort studies (6 studies evaluating rivaroxaban and 3 studies other DOACs). The follow-up period was ≥ 1 month in all studies. DOACs reduced VTE recurrence from 11.45% to 9.01% (absolute risk reduction [ARR] 2.44%), with a relative risk (RR) of 0.72 (95% confidence interval [CI] 0.60-0.85) and number needed to treat (NNT) of 41 compared to LMWH. Subgroup analyses of RCTs and observational studies demonstrated a consistent reduction in VTE recurrence with DOACs. Overall, there was no statistically significant difference in major bleeding, including intracerebral, retroperitoneal, and intraspinal. Subgroup analyses of only observational studies, length of follow-up (6 and 12 months), and rivaroxaban also revealed no increased risk of bleeding. However, subgroup analysis of only RCTs did find increased risk of major bleeding with DOACs (RR 1.78, 95% CI 1.11-2.87).
CaveatsThis meta-analysis possesses several limitations. The 2 RCTs demonstrating increased rates of major bleeding with DOACs primarily involved the gastrointestinal (GI) tract.12, 13 However, both studies included a large number of patients with GI malignancies, and these studies were industry sponsored. It is unclear whether DOACs may be safer in patients without GI tract malignancies, and further data are needed. The definition of active cancer was not consistent in the included studies, and not all studies classified the cancer types or stages. Many studies also did not specify the type or the chronicity of VTE. Included studies evaluated different DOACs and LMWH comparators. This meta-analysis included predominately observational studies, which can introduce confounders and selection bias. While these studies demonstrated incidences of recurrent VTE similar to RCTs, differences in the baseline characteristics of patients and potential unidentified confounders can introduce bias. Follow-up and duration of therapy varied in the included studies, producing a potential source of heterogeneity.
This meta-analysis suggests cancer patients who receive DOACs have significantly reduced risk of VTE when compared to LMWH, with the best evidence found with rivaroxaban. The risk of major bleeding is less clear, as data across all studies fail to show a difference, but RCT data suggest increased harm. In the context of this study, DOACs remain a viable option to reduce risk of VTE in cancer patients, particularly among patients at low risk of bleeding. Their oral administration and lack of required monitoring is patient-centric and likely improves compliance.14 We have assigned a color recommendation of Yellow (Unclear if Benefits) based upon the benefit for reduction of VTE, but potential increased risk of major bleeding reported in RCTs. Larger, high-quality RCTs are needed to establish with more certainty the promising benefits suggested by these data, as well as further study of the effects of cancer type and specific DOAC medication.
The original manuscript was published in Academic Emergency Medicine as part of the partnership between TheNNT.com and AEM.
AuthorBrit Long, MD; Alex Koyfman, MD; Michael Gottlieb, MD, RDMS
Supervising Editor: James McCormack, MD; Gary Green, MD
Published/UpdatedOctober 1, 2019
Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005. 6:401–410.
Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122:1712–1723.
Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315– 352.
Lyman GH, Bohlke K, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update. J Oncol Pract. 2015;11:e442–e444.
Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17:e452–e466.
Khorana AA, Yannicelli D, McCrae KR, Milentijevic D, Crivera C, Nelson WW, et al. Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed? Thromb Res. 2016;145:51–53.
van der Wall SJ, Klok FA, den Exter PL, Barrios D, Morillo R, Cannegieter SC, et al. Continuation of low-molecular weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study
Streiff MB, Holmstrom B, Angelini D, Ashrani A, Bockenstedt PL, Chesney C, et al. NCCN guidelines insights: cancer associated venous thromboembolic disease. J Natl Compr Cancer Netw. 2018;16:1289–1303.
Khorana AA, Noble S, Lee AYY, Soff G, Meyer G, O’Connell C, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16:1891–1894.
Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Kuderer NM, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2189– 204.
Dong Y, Wang Y, Ma RL, Liu M, Gao JZ, Su WY, et al. Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer: a systematic review and meta-analysis. J Thromb Thrombolysis. 2019 May 6. doi: 10.1007/s11239-019- 01871-4.
Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378:615– 624.
Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized TRIAL (SELECT-D). J Clin Oncol. 2018;36:2017–2023.